| Cervical cancer in low and middle‑income countries R Hull, M Mbele, T Makhafola, C Hicks, SM Wang, RM Reis, R Mehrotra, ... Oncology letters 20 (3), 2058-2074, 2020 | 287 | 2020 |
| Artificial intelligence (AI) and big data in cancer and precision oncology Z Dlamini, FZ Francies, R Hull, R Marima Computational and structural biotechnology journal 18, 2300-2311, 2020 | 236 | 2020 |
| Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options FZ Francies, R Hull, R Khanyile, Z Dlamini American journal of cancer research 10 (5), 1568, 2020 | 161 | 2020 |
| Modification by ubiquitin-like proteins: significance in apoptosis and autophagy pathways UF Cajee, R Hull, M Ntwasa International journal of molecular sciences 13 (9), 11804-11831, 2012 | 62 | 2012 |
| Translocator protein (TSPO) as a potential biomarker in human cancers NH Bhoola, Z Mbita, R Hull, Z Dlamini International journal of molecular sciences 19 (8), 2176, 2018 | 58 | 2018 |
| African medicinal plants and their derivatives: Current efforts towards potential anti-cancer drugs M Mbele, R Hull, Z Dlamini Experimental and Molecular Pathology 103 (2), 121-134, 2017 | 56 | 2017 |
| Abnormalities in alternative splicing in diabetes: therapeutic targets Z Dlamini, F Mokoena, R Hull Journal of molecular endocrinology 59 (2), R93-R107, 2017 | 50 | 2017 |
| Colorectal cancer genetics, incidence and risk factors: in search for targeted therapies R Hull, FZ Francies, M Oyomno, Z Dlamini Cancer management and research, 9869-9882, 2020 | 49 | 2020 |
| Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets Z Mbita, R Hull, Z Dlamini Viruses 6 (8), 3181-3227, 2014 | 42 | 2014 |
| The role of microRNAs in kidney disease S Mukhadi, R Hull, Z Mbita, Z Dlamini Non-coding RNA 1 (3), 192-221, 2015 | 33 | 2015 |
| Abnormalities in alternative splicing of apoptotic genes and cardiovascular diseases Z Dlamini, SC Tshidino, R Hull International journal of molecular sciences 16 (11), 27171-27190, 2015 | 32 | 2015 |
| Can the HIV-1 splicing machinery be targeted for drug discovery? Z Dlamini, R Hull HIV/AIDS-Research and Palliative Care, 63-75, 2017 | 29 | 2017 |
| Therapeutic potential of antimicrobial peptides from insects R Hull, R Katete, M Ntwasa Biotechnol Mol Biol Rev 7 (2), 31-47, 2012 | 29 | 2012 |
| The role played by alternative splicing in antigenic variability in human endo-parasites R Hull, Z Dlamini Parasites & vectors 7, 1-19, 2014 | 25 | 2014 |
| A multinational review: oesophageal cancer in low to middle‑income countries R Hull, M Mbele, T Makhafola, C Hicks, SM Wang, RM Reis, R Mehrotra, ... Oncology letters 20 (4), 1-1, 2020 | 24 | 2020 |
| MicroRNA and alternative mRNA splicing events in cancer drug response/resistance: potent therapeutic targets R Marima, FZ Francies, R Hull, T Molefi, M Oyomno, R Khanyile, ... Biomedicines 9 (12), 1818, 2021 | 22 | 2021 |
| Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis R Marima, R Hull, C Penny, Z Dlamini Mutation Research/Reviews in Mutation Research 787, 108376, 2021 | 22 | 2021 |
| MicroRNA interrelated epithelial mesenchymal transition (EMT) in glioblastoma BP Setlai, R Hull, RM Reis, C Agbor, MA Ambele, TV Mulaudzi, Z Dlamini Genes 13 (2), 244, 2022 | 21 | 2022 |
| AI and precision oncology in clinical cancer genomics: From prevention to targeted cancer therapies-an outcomes based patient care Z Dlamini, A Skepu, N Kim, M Mkhabele, R Khanyile, T Molefi, S Mbatha, ... Informatics in Medicine Unlocked 31, 100965, 2022 | 20 | 2022 |
| The catastrophic HPV/HIV dual viral oncogenomics in concert with dysregulated alternative splicing in cervical cancer R Marima, R Hull, G Lolas, KN Syrigos, M Kgoebane-Maseko, ... International Journal of Molecular Sciences 22 (18), 10115, 2021 | 20 | 2021 |
